Am J Surg Pathol

1. TRECOURT A, Scard C, Descotes F, Lopez J, et al
   Molecular Relationship Between Ovarian Sertoli-Leydig Cell Tumors and Their Heterologous Elements: Emphasis on the Possible Prognostic Significance of TERT Pathogenic Variants.
   Am J Surg Pathol. 2025 Nov 19. doi: 10.1097/PAS.0000000000002493.
   

   >> Share

   
   

   
   Clin Cancer Res

2. BRODSKY AL, Asare A, Fellman B, Anderson K, et al
   Combination Therapy with Copanlisib and Niraparib in Patients with Recurrent Endometrial and Ovarian Cancer (COPANIRA): Efficacy, Toxicity, and Translational Insights.
   Clin Cancer Res. 2026 Jan 13. doi: 10.1158/1078-0432.CCR-25-1616.
   

   >> Share

   
   

   
   Gynecol Oncol

3. ANNUNZIATA CM
   Towards personalizing PARP inhibitor maintenance therapy for ovarian cancer.
   Gynecol Oncol. 2026;204:A1-A2.
   

   >> Share

   
   
4. SMITH HJ, Dinkins K, Liang MI, Chu DI, et al
   Feasibility of a mobile health platform for patient education and remote symptom monitoring in patients with advanced ovarian cancer undergoing primary chemotherapy.
   Gynecol Oncol. 2026;205:27-31.
   

   >> Share

   
   
5. DING M, Li X, Wang H, Jia X, et al
   G-M6, an oleanane triterpenoid, represents a novel scaffold for PARP1 inhibition and anticancer activity.
   Gynecol Oncol. 2026;204:9-16.
   

   >> Share

   
   
6. FURUYA RL, Grither W, Evans MG, Wu S, et al
   Comparison of breast and gastric HER2 immunohistochemistry (IHC) scoring criteria in the assessment of endometrial carcinoma.
   Gynecol Oncol. 2025;204:17-22.
   

   >> Share

   
   

   
   Hum Pathol

7. YANG F, Liu Y, Wang Y, Yang J, et al
   Ovarian GLI1 fusion tumors Mimicking Sex Cord-Stromal Tumors: Clinicopathological and Molecular Characterization of a Five-Case Series.
   Hum Pathol. 2025 Dec 9:106003. doi: 10.1016/j.humpath.2025.106003.
   

   >> Share

   
   

   
   Int J Cancer

8. AZAM Z, Zhang X, Wahab R, Hasan MM, et al
   Doppel as an early-stage biomarker promoting EMT and dissemination in ovarian cancers.
   Int J Cancer. 2025 Nov 29. doi: 10.1002/ijc.70268.
   

   >> Share

   
   

   
   Int J Gynaecol Obstet

9. ATILGAN AE, Dilmac AE, Akcaoglu T
   Pseudo-Meigs syndrome owing to a retained fibroid following total laparoscopic hysterectomy for multiple leiomyomas: A case report and review of the literature.
   Int J Gynaecol Obstet. 2025 Aug 14. doi: 10.1002/ijgo.70474.
   

   >> Share

   
   
10. JHANG H, Kim S, Park HT, Shin JY, et al
    Dienogest use and the risk of breast and gynecologic cancers: A nationwide population-based study.
    Int J Gynaecol Obstet. 2025 Jul 29. doi: 10.1002/ijgo.70424.
    

    >> Share

    
    

    
    Obstet Gynecol

11. ERDEN M, Rehman S, Oh C, Schwartz BM, et al
    Fertility-Sparing Treatments in Patient With Gynecologic Cancers.
    Obstet Gynecol. 2025 Dec 4. doi: 10.1097/AOG.0000000000006141.
    

    >> Share

    
    

    
    Oncogene

12. SUN J, Cai X, Yung MMH, Zhou W, et al
    Retraction Note: miR-137 mediates the functional link between c-Myc and EZH2 that regulates cisplatin resistance in ovarian cancer.
    Oncogene. 2026 Jan 16. doi: 10.1038/s41388-026-03676.
    

    >> Share

    
    

    
    Oncol Rep

13. ZHONG Y, Le F, Cheng J, Luo C, et al
    

    [Corrigendum] Triptolide inhibits JAK2/STAT3 signaling and induces lethal autophagy through ROS generation in cisplatin?resistant SKOV3/DDP ovarian cancer cells
    
    

    .
    Oncol Rep. 2026;55:43.
    

    >> Share

    
    

Free Medical Abstracts
Privacy Policy
Sponsors
Share